A couple of weeks ago, I went to my business PO Box expecting to see a few letters, a magazine or two, and an assortment of domain name renewal notices and other junk mail. When I saw the yellow slip in the box indicating a package awaited my attention behind the mail counter, my heart skipped a beat in excitement.
Anything.com, a domain Investment company that owns a portfolio of high value domain name assets, has sold the Medicine.com domain name. The sale of Medicine.com was first reported by Jamie Zoch in a tweet earlier this morning:
Hampstead Trust of New Zealand acquires ULTRA premium, generic domain name Medicine(.)com from Anything(.)com LTD. according to whois records. #medicine #domain What do you think it sold for? Site says launching in Q2 2019! #bigone pic.twitter.com/5fux4NKRw5
— Jamie Zoch (@DotWeekly) February 22, 2019
I tend to buy my most valuable domain names in private acquisitions. Oftentimes, the domain names I want to buy are owned by companies that no longer need these domain names. I have found that sometimes the domain names were acquired by the current registrant as a result of a corporate acquisition. If I have this information, I like to mention it in my offer or introductory email.
Natasa Djukanovic is the Chief Marketing Officer of the .ME registry, a ccTLD extension from the country of Montenegro. As you probably know, .ME has been positioned as a mainstream generic TLD with an alternative meaning to its country code utility, since its domain names became available to register a little over ten years ago.
Thrive Global, an online publication founded by Ariana Huffington, recently published an interview with Natasa, and it is a good read. The interview offers some background about the .ME registry team along with some of its early marketing and promotion strategy. Here’s a brief excerpt of Natasha sharing some background about .ME:
A UDRP panel ruled that the CellGene.com UDRP was a case of Reverse Domain Name Hijacking. The UDRP was filed at the World Intellectual Property Organization, and it is case #D2018-2673. The UDRP was filed by a large publicly traded pharmaceutical company called Celgene.